FDA Accepts Bayer's Filing To Expand KERENDIA Use In CKD Without Diabetes
(RTTNews) - Thursday, Bayer (BYR.L) announced that the U.S. FDA has accepted its supplemental New Drug Application (sNDA) for KERENDIA (finerenone) to treat adults with non-diabetic chronic kidney disease (CKD).
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.